COMPASS Pathways has presented new, positive data demonstrating the potential of COMP360 psilocybin therapy in depression at the Annual Meeting of the American College of Neuropsychopharmacology...
Filament Health has been issued two new patents for the extraction and standardisation of natural psilocybin and associated psychedelic compounds.
A team of researchers at the University of Pennsylvania School of Medicine have published findings which show how ketamine dramatically reorganises activity in the brain –...
Awakn Life Sciences has announced that it has signed a five-year lease to open Awakn Clinics Trondheim.
Psyrise, a mental health marketing company located in South Florida, has released a first-of-its-kind marketing platform for health practitioners in the field of psychedelic therapies.
Irwin Naturals is branching into the psychedelics space with the aim of establishing the world’s largest chain of psychedelic mental health clinics.
An increasing amount of research is investigating the efficacy of psychedelic mushrooms for the treatment of a number of health conditions, however, knowledge about how psychedelic...
KGK Science and Nova Mentis Life Science will carry out a Phase 2a clinical trial testing the efficacy of psilocybin microdosing on Fragile X Syndrome.
Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.
Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.